CLOV

CLOVER HEALTH INVESTMENTS CORP

Healthcare | Small Cap

$0.03

EPS Forecast

$699.8

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-07-20

Clover Health Q1 2026: A Clover-Leaf Turn Toward Profitability Keeps Growing, With a Side of Guidance

Ticker: CLOV — Earnings snapshot, EPS considerations, and a revenue forecast that hints at a durable growth story for the Medicare Advantage player. This report reads like a thesis on how fast growth can coexist with a path to GAAP profitability, and what that implies for peers in the regulated, risk-based care space.

Lead: A growth engine that finally backs up the engine room

Clover Health Investments, Corp. (Nasdaq: CLOV) released its first quarter 2026 results from Wilmington, Delaware on May 6, 2026. The headline figures show a company growing fast where it counts—revenue, membership, and operating leverage—but with a twist: GAAP Net Income of $27 million, up $29 million versus the year-ago period. The story isn’t that Clover merely grew; it’s that growth appears to be translating into tangible profitability at the GAAP line, a detail investors will cross-check against EPS and EPS consensus in the next reporting cycle.

Key quarterly highlights

  • Medicare Advantage membership of 155,773, up 51% year-over-year.
  • Total revenues of $749 million, up 62% year-over-year.
  • Consolidated Gross Profit of $160 million, up 47% year-over-year.
  • Adjusted EBITDA of $40 million, up 56% year-over-year.

Guidance and the revenue forecast for 2026

For the full year 2026, Clover outlined a revenue forecast between $2.81 billion and $2.92 billion, with the midpoint implying roughly 49% growth year-over-year. The company also targets:

  • Average Medicare Advantage membership around 154,000–158,000 (midpoint representing about 46% growth).
  • Consolidated Gross Profit in a range of $470 million–$510 million, about 38% growth at the midpoint.
  • Adjusted EBITDA between $50 million and $70 million.
  • GAAP Net Income between $0 million and $20 million.

In plain terms, the trajectory suggests the company intends to sustain growth while steering toward GAAP profitability—even if per-share (EPS) metrics aren’t spelled out in the press release. Investors will be watching how the EPS figure stacks up to consensus once per-share data is disclosed, determining whether the quarter is an early earnings surprise or a close call on earnings expectations.

Leadership commentary and what it signals

“Our results demonstrate the differentiated model we have built to drive growth and profitability while expanding access to high-quality, affordable care through a wide-network PPO,” said Clover Health CEO Andrew Toy. “During the first quarter, we delivered strong performance across key metrics, driven by deeper clinical engagement, with Clover Assistant supporting earlier intervention and better outcomes for our members. As we continue to scale our technology to reach more members, we expect to achieve our first full year of GAAP Net Income profitability in 2026.”
“We achieved positive GAAP Net Income in the first quarter of 2026 while continuing to grow at a market-leading rate,” said Clover Health Interim CFO Clay Thornton. “Results are developing in line with our expectations, and we are encouraged by early medical cost trend indicators across both new and returning cohorts. We expect to meet or exceed our full year 2026 outlook across all metrics, including our expectation to deliver GAAP Net Income profitability.”

What this could portend for Clover and sector peers

The numbers matter not merely as a quarterly brag sheet but as a signal of whether Clover’s tech-enabled, risk-based model can sustain rapid member growth without capitulating to margin compression. The EPS discussion will matter once per-share results arrive, but the top-line vigor—revenue growth well north of 60% and a double-digit jump in gross profit—suggests that the company’s cost structure is benefiting from scale and operational discipline.

For sector peers, the message is nuanced. If Clover’s Clover Assistant and data-driven care interventions contribute meaningfully to medical-cost trends, COPs (cost of care) could trend more favorably across the industry. However, the path to mid-teens or higher profitability hinges on managing utilization, black-boxed medical costs, and regulatory cost dynamics in a way that doesn’t derail growth. In other words, a profitable quarter doesn’t become a trend without a steady hand on the cost lever.

The market will likely compare this quarter to peers' earnings and to the broader narrative around Medicare Advantage growth, private payer mix, and the economics of digital health platforms that promise higher engagement at lower marginal cost. If the revenue forecast proves durable and the EPS consensus starts to align with or beat expectations, Clover could gain a credibility boost in a sector that prizes both growth and survivability.

Bottom line: growth meets governance

Clover’s Q1 2026 results deliver a compelling view of a growth engine that is learning to run with a profits wheel. The combination of robust membership gains, a healthy revenue trajectory, and improving profitability metrics provides a framework for investors to reassess the risk-reward in CLOV’s story. The company’s ability to translate expansion into GAAP Net Income will be the critical test in the months ahead, with the 2026 guidance serving as a roadmap rather than a promise. For now, the puzzle pieces align more often than not, and the sector peers will be watching closely as the year unfolds.